Analysis of a Phase 2b Study of GEN-003, a Genital Herpes Immunotherapy, Showed Significant Reductions in Viral Shedding and Lesion Rate Vs Placebo

BACKGROUND: GEN-003 is an investigational genital herpes immunotherapy comprising gD2ΔTMR, an HSV-2 antigen that induces neutralizing antibody and T cell responses, ICP4.2, an HSV-2 T cell antigen selected through human T cell screens, and Matrix-M2™, a saponin-based adjuvant. This Phase 2b study wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Heineman, Thomas C, Bernstein, David, Wald, Anna, Van Wagoner, Nicholas, Leone, Peter, Mayer, Kenneth, Lucksinger, Gregg, Win, Sandra, Koltun, William, Desai, Nisha, Oliphant, Thomas, Natenshon, Andrew, McNeil, Lisa K, Flechtner, Jessica B, Hetherington, Seth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631773/
http://dx.doi.org/10.1093/ofid/ofx162.140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631773/
http://dx.doi.org/10.1093/ofid/ofx162.140

Ejemplares similares